Atezolizumab

Where the papers sit

37 papers from the last 6 months study atezolizumab directly · updated from PubMed 8 Oct 2026

• Atezolizumab-Bevacizumab in HCC

  Atezolizumab plus bevacizumab remains the central first-line strategy for unresectable hepatocellular carcinoma, with real-world cohorts refining survival predictors and treatment pathways. Comparisons with durvalumab plus tremelimumab, and trials adding ipilimumab, are testing sequencing and intensified combinations. Response assessment repeatedly examines RECIST, mRECIST, DCP, muscle status, and early survival dynamics. Cost, proteinuria, salvage TACE, and liver transplantation remain practical questions.

  19 papers · 51.4%

• PD-L1 Immunotherapy Combinations

  PD-L1 blockade is being paired with antiangiogenic drugs, costimulatory antibodies, kinase inhibitors, radiation, and engineered delivery systems across solid tumors. Renal and liver cancers recur clinically, while preclinical work seeks stronger tumor immunogenicity and local antibody production. Baseline immune state and myeloid remodeling are emerging as response determinants. Toxicities such as encephalitis and pernicious anemia keep safety and patient selection open.

  11 papers · 29.7%

• Atezolizumab in Lung Cancer

  Atezolizumab is moving across metastatic, neoadjuvant, and early-stage non-small cell lung cancer settings, usually with platinum chemotherapy, bevacizumab, or stereotactic radiation. Tiragolumab combinations focus on improving outcomes in PD-L1-high disease, while subcutaneous delivery addresses treatment practicality. Gut microbiota and immune-nutritional status are being explored as predictors of progression-free and overall survival. The main open issues are durable benefit, added toxicity, and which earlier-stage patients should receive combined therapy.

  7 papers · 18.9%